LeMaitre Vascular (LMAT) is back on investor radar after reporting first quarter 2026 results featuring double digit sales growth, wider margins, and increased full year guidance for sales, operating income, and EPS.

Despite the strong first quarter and higher guidance, the share price has pulled back recently. The 1 month share price return is down 15.24% after a strong run, leaving the year to date share price return at 21.38% and the 5 year total shareholder return at 102.97%. This suggests that long term momentum remains in place even as short term sentiment cools.

If strong execution in healthcare catches your eye, it may be worth widening your search using a screener focused on 32 healthcare AI stocks

With the stock now trading at a discount to analyst price targets after a sharp pullback, the key question is whether recent earnings strength is underappreciated or if the market is already correctly pricing in future growth.

Most Popular Narrative: 12.5% Undervalued

At a last close of $97.31 versus a narrative fair value of $111.22, the most followed view sees upside potential that current pricing does not fully reflect.

Strong pipeline of biologics and next-generation products, combined with ongoing regulatory wins, enhances pricing power and product mix; this supports premium pricing and improved gross margins, with successful launches expected to materially contribute to long-term earnings growth.

Curious what earnings profile and margin path sit behind that fair value estimate? The narrative leans on steady expansion, disciplined profitability, and a richer product mix to justify its view.

Result: Fair Value of $111.22 (UNDERVALUED)

However, the narrative can be shaken if pricing power proves short lived, or if execution in newer international markets runs into regulatory or supply setbacks.

Another Angle: Cash Flows Point in the Other Direction

While the consensus narrative sees LeMaitre Vascular as about 12.5% undervalued at $97.31 versus $111.22, the SWS DCF model comes out far more cautious. On that view, the stock sits above an estimated future cash flow value of $66.66, which implies an overvalued position instead.

The gap between an earnings based fair value and a cash flow based figure raises a practical question for you as an investor: which set of assumptions feels closer to how you think this business can perform over time?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out LeMaitre Vascular for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution feels familiar, act while the details are fresh and review the data yourself using the 3 key rewards and 1 important warning sign

Ready to hunt for your next idea?

While LeMaitre Vascular might be front of mind today, some of the most interesting opportunities often sit just off your radar, waiting for a closer look.

• Zero in on potential mispricings by scanning 50 high quality undervalued stocks that pair quality fundamentals with what could be appealing entry points.
• Secure your income focus by checking out 12 dividend fortresses that aim to combine higher yields with resilience through different market conditions.
• Protect the downside first by sorting for 66 resilient stocks with low risk scores that score well on balance sheet strength and overall risk profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.